"Our financial results continue to show the beneficial effects on operating expenses and cash burn resulting from the termination of the licenses to our three clinical-stage programs, the significant workforce reduction initiated last year April and successful negotiations with vendors and landlords. We are now focused on taking the steps necessary to put the Company and its three subsidiaries into the liquidation and dissolution process, including a stockholder vote expected to be held in April," said David Nassif, J.D., CEO of Sio Gene Therapies.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SIOX:
